Literature DB >> 10941934

Interleukin-8 secretion of human epithelial and monocytic cell lines induced by middle ear pathogens.

H Kita1, T Himi, N Fujii, J Ylikoski.   

Abstract

Otitis media with effusion (OME) is one of the most common diseases in children. Alloiococcus otitidis, a new gram-positive bacterial species, was isolated from the middle ear fluid of children with OME; however, the pathogenic role of this bacteria is yet unknown. In this study, the ability of cultured epithelial cell lines (Hep-2 and Hela) and monocytic cell lines (THP-1 and U 937) to secrete chemokine interleukin-8 (IL-8) in response to the A. otitidis organism and three bacterial organisms mainly detected from middle ear fluid in OME, and bacterial cell components was investigated. When stimulated with four viable bacterial cells, epithelial cells and monocytes secreted IL-8 in a time-dependent manner. The monocytes produced significantly higher levels of IL-8 than the epithelial cells. Compared with that by viable bacterial cells, IL-8 secretion by stimulated epithelial cells and monocytes was reduced when the bacteria were heated and treated with glutaraldehyde. With bacterial stimulations, cell treatment of interferon-gamma caused monocytes to increase the induction of IL-8 production, however, the induction of monocyte differentiation caused monocytes to reduce the induction of IL-8 production. Furthermore, epithelial cells and monocytes stimulated by four viable bacterial organisms physically separated from cultured cells reduced the induction of IL-8 compared with directly stimulated cells, and monocytes stimulated with soluble extracts prepared from A. otitidis organisms produced IL-8 in a dose-dependent manner. These results suggest that part of the IL-8 stimulation of the A. otitidis organism may exist in a diffusable factor released by the bacteria or soluble components of the bacteria itself.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10941934     DOI: 10.1111/j.1348-0421.2000.tb02526.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  6 in total

1.  Alveolar epithelial cell-macrophage interactions affect oxygen-stimulated interleukin-8 release.

Authors:  Matthew R Hjort; Andrew J Brenyo; Jacob N Finkelstein; Mark W Frampton; Michael B LoMonaco; Judith C Stewart; Carl J Johnston; Carl T D'Angio
Journal:  Inflammation       Date:  2003-06       Impact factor: 4.092

2.  High incidence of Alloiococcus otitidis in children with otitis media, despite treatment with antibiotics.

Authors:  Atsushi Harimaya; Ryuta Takada; Panu H Hendolin; Nobuhiro Fujii; Jukka Ylikoski; Tetsuo Himi
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

3.  Concurrent assay for four bacterial species including alloiococcus otitidis in middle ear, nasopharynx and tonsils of children with otitis media with effusion: a preliminary report.

Authors:  Emine Aydın; Eren Taştan; Mihriban Yücel; Filiz Aydoğan; Esra Karakoç; Necmi Arslan; Yunus Kantekin; Münir Demirci
Journal:  Clin Exp Otorhinolaryngol       Date:  2012-06-12       Impact factor: 3.372

4.  Bacterial aetiology of chronic otitis media with effusion in children - risk factors.

Authors:  Izabela Korona-Glowniak; Agata Wisniewska; Marek Juda; Karolina Kielbik; Grazyna Niedzielska; Anna Malm
Journal:  J Otolaryngol Head Neck Surg       Date:  2020-04-29

5.  Quantitative PCR of ear discharge from Indigenous Australian children with acute otitis media with perforation supports a role for Alloiococcus otitidis as a secondary pathogen.

Authors:  Robyn L Marsh; Michael J Binks; Jemima Beissbarth; Peter Christensen; Peter S Morris; Amanda J Leach; Heidi C Smith-Vaughan
Journal:  BMC Ear Nose Throat Disord       Date:  2012-10-03

Review 6.  Reviewing the Pathogenic Potential of the Otitis-Associated Bacteria Alloiococcus otitidis and Turicella otitidis.

Authors:  Rachael Lappan; Sarra E Jamieson; Christopher S Peacock
Journal:  Front Cell Infect Microbiol       Date:  2020-02-14       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.